ClinicalTrials.gg
CompletedNCT00730613Updated Oct 1, 2026

Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma

A Phase 1 interventional study of therapeutic autologous lymphocytes and gene expression analysis in Brain and Central Nervous System Tumors, sponsored by City of Hope Medical Center. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 years 4 months after the study started (first participant enrolled Mar 2002, registered Aug 2008).
Updated Oct 1, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

RATIONALE: Cellular adoptive immunotherapy may stimulate the immune system in different ways and stop cancer cells from growing.

PURPOSE: This clinical trial is studying the side effects of cellular adoptive immunotherapy using genetically modified T-lymphocytes and to see how well it works in treating patients with recurrent or refractory high-grade malignant glioma.

Read the detailed description

OBJECTIVES:

Primary

  • To assess the feasibility and safety of cellular immunotherapy utilizing ex vivo expanded autologous CD8-positive T-cell clones genetically modified to express the IL-13 zetakine chimeric immunoreceptor and the Hy/TK selection/suicide fusion protein in patients with recurrent or refractory, high-grade malignant glioma.

Secondary

  • To evaluate the antitumor activity of adoptively transferred clones in these patients.
  • To screen for the development of anti-IL13 zetakine and anti-HyTK immune responses in these patients.
  • To evaluate the efficacy of ganciclovir administration for ablating transferred clones in vivo should toxicity be encountered.

OUTLINE:

  • Leukapheresis and therapy preparation: Patients undergo leukapheresis to obtain peripheral blood mononuclear cells. T-cells isolated from the peripheral blood are then genetically modified, hygromycin-resistant cloned, expanded ex vivo, and cryopreserved until the first clinical or radiographic evidence of recurrence or progression. Patients with documented disease recurrence or progression undergo re-biopsy or re-resection of the tumor and placement of a reservoir-access device (Rickham shunt) into the tumor resection cavity prior to autologous T-cell clone infusion therapy.
  • Autologous T-cell clone infusion: Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving tumor regression with residual disease by MRI after 4 courses of study therapy may receive up to 2 additional courses in the absence of disease progression, unacceptable toxicity, or a complete response.

Patients undergo blood, cerebrospinal fluid, and tissue sample collection periodically for correlative studies. Samples are assessed for IL13Rα2 expression levels, susceptibility to redirected T-cell effector mechanisms, and other tumor and T-cell activation markers.

After completion of study treatment, patients will be followed monthly for 3 months, then every 3 months for two years, and then annually for at least 15 years.

02

Conditions studied

  • Brain and Central Nervous System Tumors

Keywords

  • adult anaplastic astrocytoma
  • adult diffuse astrocytoma
  • adult pilocytic astrocytoma
  • adult subependymal giant cell astrocytoma
  • adult anaplastic ependymoma
  • adult ependymoma
  • adult myxopapillary ependymoma
  • adult subependymoma
  • adult anaplastic oligodendroglioma
  • adult oligodendroglioma
  • adult brain stem glioma
  • adult giant cell glioblastoma
  • adult glioblastoma
  • recurrent adult brain tumor
  • adult gliosarcoma
  • adult mixed glioma
  • adult pineal gland astrocytoma
03

In context

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 65 are open to participants now.

This study's enrollment of 3 is below the median of 35 across 487 interventional studies indexed under Central Nervous System Neoplasms.

Browse Central Nervous System Neoplasms studies →

Lead sponsor

City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed malignant glioma at original diagnosis

    • Grade III or IV disease
    • or recurrent disease
    • Unifocal site of original disease in cerebral cortex
  • No clinical evidence of progressive encephalopathy
  • Has not undergone recent re-resection of recurrent or progressive disease
  • No communication between the tumor resection cavity and the ventricles and deep cerebrospinal fluid pathways as documented by post-operative MRI scan

PATIENT CHARACTERISTICS:

  • performance status 70-100%
  • > 3 months
  • WBC ≥ 2,000/dL
  • > 1,000/dL
  • count ≥ 100,000/dL (unsupported by transfusion or growth factor)
  • Creatinine \< 1.6 mg/dL
  • \< 1.5
  • and SGPT \< 2 times
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective
  • Able to understand protocol basic elements and/or risks/benefits of participating in this pilot study
  • No requirement for supplemental oxygen to keep saturation > 95% that is not expected to resolve within 2 weeks
  • No uncontrolled cardiac arrhythmia
  • No hypotension requiring pressor support
  • No renal dialysis dependency
  • No refractory seizure disorder
  • No concurrent non-malignant illness that is poorly controlled with treatment or is of such severity the investigators deem it unwise to enter the patient on protocol
  • No severe infection for which patient is being treated
  • No history of ganciclovir and/or Prohance contrast allergy or intolerance
  • No positivity within the past 3 months

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • Must have recovered from major surgery
  • At least 4 weeks since primary therapy and no dependence
  • At least 2 weeks since prior cytotoxic chemotherapy and recovered
  • No concurrent systemic corticosteroids, except for use in managing T-cell therapy toxicity
  • No concurrent immunotherapy (i.e., interferons, vaccines, or other cellular products)
  • No concurrent pentoxifylline
  • No other concurrent investigative agents
  • No concurrent ganciclovir or ganciclovir derivative
  • No concurrent acyclovir for non-life threatening herpes virus infection
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Treatment (therapeutic autologous lymphocytes)

    Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.

    Biological: therapeutic autologous lymphocytes · Genetic: gene expression analysis · Other: laboratory biomarker analysis

Interventions

  • Cycles of escalating cell dose infusions up to the target cell dose of 10(8)

  • Geneticgene expression analysis

    At the time of excess pathology samples documenting response/relapse

  • Otherlaboratory biomarker analysis

    CSF generated at the time of each T-cell dose

06

What researchers measure

Primary outcomes

  1. Feasibility

    Time frame: 1 year after the end of treatment on study

  2. Safety

    Time frame: 1 year after the end of treatment on study

Secondary outcomes

  1. Anti-tumor activity of adoptively transferred clones

    Time frame: 1 year after the end of treatment on study

  2. Anti-IL 13 zetakine and anti-HyTK immune response in patients

    Time frame: 1 year after the end of treatment on study

  3. Efficacy of ganciclovir for clone ablation (in the event of toxicity)

    Time frame: 1 year after the end of treatment on study

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2002 to primary completion in Aug 2011, 112 months.

Of 43 non-industry phase 1 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 73. This study's 112 months is above that.

Counting every sponsor, half of 52 studies reached it within 46 months; a quarter within 37 and three quarters within 73.

Start moved once since we started tracking on Sep 25, 2026: Feb 2002 → Mar 2002, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2008
First posted
Aug 8, 2008
StartActual
Mar 25, 2002was Feb 2002
Primary completionActual
Aug 1, 2011
CompletionActual
Aug 1, 2011
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2002→Mar 25, 2002 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Feb 2002→Mar 25, 2002 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00730613
Responsible party
Sponsor
First posted
Aug 8, 2008
Start date
Mar 25, 2002
Primary completion
Aug 1, 2011
Completion
Aug 1, 2011
Last update
Oct 1, 2026

Study contacts

Stephen Forman, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Therapeutic Autologous Lymphocytes

Start the discussion